Free tool
FAERS Monitor: Onfi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203993 or its brand name (Onfi, Clobazam). Reports on generic versions are filed under their own applications.
Reports
24,918
Serious
19,680
79% of reports
Hospitalization
8,481
Death reported
1,592
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- seizure5,137
- drug ineffective3,354
- off label use2,341
- somnolence1,987
- drug interaction1,200
- fatigue1,179
- epilepsy870
- condition aggravated859
- generalised tonic-clonic seizure774
- status epilepticus738
- pneumonia719
- aggression715
- product use in unapproved indication713
- fall691
- decreased appetite670
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 46 |
| 2005 | 73 |
| 2006 | 69 |
| 2007 | 84 |
| 2008 | 111 |
| 2009 | 127 |
| 2010 | 168 |
| 2011 | 140 |
| 2012 | 656 |
| 2013 | 723 |
| 2014 | 787 |
| 2015 | 997 |
| 2016 | 1,142 |
| 2017 | 1,303 |
| 2018 | 1,257 |
| 2019 | 2,057 |
| 2020 | 1,917 |
| 2021 | 2,650 |
| 2022 | 2,014 |
| 2023 | 2,184 |
| 2024 | 2,401 |
| 2025 | 2,226 |
| 2026 | 1,785 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,029,241 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| status epilepticusSignal | 738 | 59.0 | 54.8 | 39,268 |
| generalised tonic-clonic seizureSignal | 774 | 41.4 | 38.5 | 29,048 |
| seizureSignal | 5,137 | 39.2 | 38.3 | 183,894 |
| epilepsySignal | 870 | 24.7 | 23.1 | 19,221 |
| aggressionSignal | 715 | 12.2 | 11.4 | 7,266 |
| somnolenceSignal | 1,987 | 8.4 | 8.1 | 12,947 |
| drug interactionSignal | 1,200 | 6.4 | 6.1 | 5,492 |
| decreased appetiteSignal | 670 | 2.4 | 2.3 | 572 |
| product use in unapproved indicationSignal | 713 | 2.4 | 2.3 | 605 |
| condition aggravatedSignal | 859 | 2.4 | 2.2 | 700 |
| off label useSignal | 2,341 | 2.3 | 2.2 | 1,710 |
| drug ineffectiveSignal | 3,354 | 2.2 | 2.1 | 2,197 |
| pneumonia | 719 | 1.9 | 1.7 | 297 |
| fall | 691 | 1.8 | 1.6 | 226 |
| fatigue | 1,179 | 1.3 | 1.2 | 74 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.